Split decision

FRAMINGHAM (02/27/2004) - Pharmacopeia Inc. plans to separate its drug discovery and software businesses into two independent companies. Wholly owned subsidiary Pharmacopeia Drug Discovery will be spun off to stockholders, and is expected to apply for its own NASDAQ listing. Pharmacopeia, meanwhile, will officially change its name to Accelrys and focus on scientific software development. Mark J. Emkjer, president of Pharmacopeia's software unit, is expected to become president and CEO of Accelrys.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

More about PharmacopeiaScientific Software

Show Comments